Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2022 Feb 3;14(2):315.
doi: 10.3390/v14020315.

Comparison of the Anti-SARS-CoV-2 Surrogate Neutralization Assays by TECOmedical and DiaPROPH-Med with Samples from Vaccinated and Infected Individuals

Lennart Münsterkötter  1 , Moritz Maximilian Hollstein  2 , Andreas Hahn  3 , Andrea Kröger  4   5 , Moritz Schnelle  6 , Luise Erpenbeck  2   7 , Uwe Groß  1 , Hagen Frickmann  3   8 , Andreas Erich Zautner  1   4
Affiliations
Comparative Study

Comparison of the Anti-SARS-CoV-2 Surrogate Neutralization Assays by TECOmedical and DiaPROPH-Med with Samples from Vaccinated and Infected Individuals

Lennart Münsterkötter et al. Viruses. .

Abstract

Anti-SARS-CoV-2-specific serological responses are a topic of ongoing evaluation studies. In the study presented here, the anti-SARS-CoV-2 surrogate neutralization assays by TECOmedical and DiaPROPH -Med were assessed in a head-to-head comparison with serum samples of individuals after vaccination as well as after previous infection with SARS-CoV-2. In case of discordant results, a cell culture-based neutralization assay was applied as a reference standard. The TECOmedical assay showed sensitivity and specificity of 100% and 61.3%, respectively, the DiaPROPH-Med assay 95.0% and 48.4%, respectively. As a side finding of the study, differences in the likelihood of expressing neutralizing antibodies could be shown for different exposition types. So, 60 of 81 (74.07%) of the samples with only one vaccination showed an expression of neutralizing antibodies in contrast to 85.71% (60 of 70 samples) of the samples with two vaccinations and 100% (40 of 40) of the samples from previously infected individuals. In conclusion, the both assays showed results similar to previous assessments. While the measured diagnostic accuracy of both assays requires further technical improvement of this diagnostic approach, as the calculated specificity values of 61.3% and 48.4%, respectively, appear acceptable for diagnostic use only in populations with a high percentage of positive subjects, but not at expectedly low positivity rates.

Keywords: COVID-19; SARS-CoV-2; neutralization; serology; test comparison; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Principle of the TECOmedical SARS-CoV-2 Neutralization Antibody ELISA. (A) Serum samples and conjugate (HRP-labelled SARS-CoV-2-SP-RBD) are premixed. (B) During incubation, neutralizing antibodies (anti-SARS-CoV-2-RBD-IgG) and the conjugate form antibody–antigen complexes. (C) The mixture is added to the solid phase; preformed complexes are unable to interact with ACE2-receptors; unbound conjugate can interact freely. (D) Tetramethylbenzide substrate is added and reacts with HRP; the measured optical density is inversely correlated with the concentration of neutralizing antibodies. Yellow square: color change after enzymatic reaction.
Figure 2
Figure 2
Principle of the DIA-SARS-CoV-2-nAb assay. (A) Serum samples and conjugate (HRP-labelled recombinant SARS-CoV-2-spike-protein) are simultaneously added to the solid phase. (B) Present neutralizing antibodies (anti-SARS-CoV-2-RBD-IgG) are bound to the conjugate and consequently block the interaction between the receptor-binding domain of the spike protein and recombinant human ACE-2-receptors on the solid phase. (C) Tetramethylbenzide substrate is added and reacts with HRP; the measured optical density is inversely correlated with the concentration of neutralizing antibodies in the sample. Yellow square: color change after enzymatic reaction.
Figure 3
Figure 3
Principle of the DIA-SARS-CoV-2-S-IgG-av avidity assay. (A) Serum samples are added to the solid phase in duplicate (reference wells and test wells); present anti-SARS-CoV-2-RBD-IgG are bound to the antigen (recombinant SARS-CoV-2-spike protein) on the solid phase. (B) The test wells are treated with dissociation solution to destroy antibody-antigen complexes formed by low avidity antibodies. (C) Remaining antibody-antigen complexes are detected by the conjugate (HRP-labelled monoclonal anti-human-IgG). (D) Tetramethylbenzide substrate is added and reacts with HRP; the reference well indicates whether the sample contains a sufficient amount of IgG or not, if the first applies, the test well is used to calculate the RAI (Relative Avidity Index). Yellow square: color change after enzymatic reaction.
See this image and copyright information in PMC

References

    1. Singanayagam A., Hakki S., Dunning J., Madon K.J., Crone M.A., Koycheva A., Derqui-Fernandez N., Barnett J.L., Whitfield M.G., Varro R., et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: A prospective, longitudinal, cohort study. Lancet Infect. Dis. 2022;22:183–195. doi: 10.1016/S1473-3099(21)00648-4. - DOI - PMC - PubMed
    1. Espejo A.P., Akgun Y., Al Mana A.F., Tjendra Y., Millan N.C., Gomez-Fernandez C., Cray C. Review of current advances in serologic testing for COVID-19. Am. J. Clin. Pathol. 2020;154:293–304. doi: 10.1093/ajcp/aqaa112. - DOI - PMC - PubMed
    1. Gundlapalli A.V., Salerno R.M., Brooks J.T., Averhoff F., Petersen L.R., McDonald L.C., Iademarco M.F., CDC COVID-19 Response SARS-CoV-2 serologic assay needs for the next phase of the US COVID-19 pandemic response. Open Forum Infect. Dis. 2020;8:ofaa555. doi: 10.1093/ofid/ofaa555. - DOI - PMC - PubMed
    1. Emmerich P., Murawski C., Ehmen C., von Possel R., Pekarek N., Oestereich L., Duraffour S., Pahlmann M., Struck N., Eibach D., et al. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin. Trop. Med. Int. Health. 2021;26:621–631. doi: 10.1111/tmi.13569. - DOI - PMC - PubMed
    1. Sariol C.A., Pantoja P., Serrano-Collazo C., Rosa-Arocho T., Armina A., Cruz L., Stone E.T., Arana T., Climent C., Latoni G., et al. Function is more reliable than quantity to follow up the humoral response to the receptor binding domain of SARS- CoV-2 spike protein after natural infection or COVID-19 vaccination. medRxiv. 2021 doi: 10.3390/v13101972. - DOI - PMC - PubMed

Publication types